Acute lymphoblastic leukemia, version 2.2015 Journal Article


Authors: Alvarnas, J. C.; Brown, P. A.; Aoun, P.; Ballen, K. K.; Barta, S. K.; Borate, U.; Boyer, M. W.; Burke, P. W.; Cassaday, R.; Castro, J. E.; Coccia, P. F.; Coutre, S. E.; Damon, L. E.; De Angelo, D. J.; Douer, D.; Frankfurt, O.; Greer, J. P.; Johnson, R. A.; Kantarjian, H. M.; Klisovic, R. B.; Kupfer, G.; Litzow, M.; Liu, A.; Rao, A. V.; Shah, B.; Uy, G. L.; Wang, E. S.; Zelenetz, A. D.; Gregory, K.; Smith, C.
Article Title: Acute lymphoblastic leukemia, version 2.2015
Abstract: Treatment of acute lymphoblastic leukemia (ALL) continues to advance, as evidenced by the improved risk stratification of patients and development of newer treatment options. Identification of ALL subtypes based on immunophenotyping and cytogenetic and molecular markers has resulted in the inclusion of Philadelphia-like ALL and early T-cell precursor ALL as subtypes that affect prognosis. Identification of Ikaros mutations has also emerged as a prognostic factor. In addition to improved prognostication, treatment options for patients with ALL have expanded, particularly with regard to relapsed/refractory ALL. Continued development of second-generation tyrosine kinase inhibitors and the emergence of immunotherapy, including blinatumomab and chimeric antigen receptor T-cell therapy, have improved survival. Furthermore, incorporation of minimal residual disease (MRD) monitoring has shown insight into patient outcomes and may lead to treatment modification or alternative treatment strategies in select populations. This excerpt focuses on the sections of the ALL guidelines specific to clinical presentation and diagnosis, treatment of relapsed/refractory ALL, and incorporation of MRD monitoring. To view the most recent complete version of these guidelines, visit NCCN.org. © JNCCN-Journal of the National Comprehensive Cancer Network.
Journal Title: Journal of the National Comprehensive Cancer Network
Volume: 13
Issue: 10
ISSN: 1540-1405
Publisher: Harborside Press  
Date Published: 2015-10-01
Start Page: 1240
End Page: 1279
Language: English
PROVIDER: scopus
PUBMED: 26483064
DOI/URL:
Notes: Export Date: 2 November 2015 -- Source: Scopus
Citation Impact
MSK Authors
  1. Andrew D Zelenetz
    767 Zelenetz
  2. Dan Douer
    87 Douer
Related MSK Work